Exicure Inc (XCUR)
NASDAQ:XCUR
Top Page
Exicure
(NASDAQ:XCUR)
Select Model
Select Model
Rating:43Neutral
Price Target:
$4.00
▼(-32.55% Downside)
Action:ReiteratedDate:04/03/26
The score is weighed down primarily by weak financial performance—ongoing losses, unstable revenue, and persistent cash burn—despite reduced leverage. Technicals add a mild headwind with price below key longer-term moving averages, while corporate events are mixed (legal resolution and clinical progress offset by leadership disruption).
Positive Factors
Proprietary SNA platform
The proprietary spherical nucleic acid (SNA) platform is a durable competitive asset: it enables differentiated nucleic-acid delivery and can be applied across oncology and immunology programs, supporting multiple candidate opportunities and partnership interest over time.
Negative Factors
Persistent heavy cash burn
Consistently negative operating and free cash flow implies ongoing reliance on external financing, partnerships, or dilution. Heavy burn reduces runway and forces strategic trade-offs, creating a sustained solvency and execution risk until cash generation stabilizes.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary SNA platform
The proprietary spherical nucleic acid (SNA) platform is a durable competitive asset: it enables differentiated nucleic-acid delivery and can be applied across oncology and immunology programs, supporting multiple candidate opportunities and partnership interest over time.
Read all positive factors
Exicure (XCUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.71M
Dividend YieldN/A
Average Volume (3M)23.77K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth-100.00%
EPS Growth33.44%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.46
Shares Outstanding6,373,915
10 Day Avg. Volume33,737
30 Day Avg. Volume23,774
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-147.37
Enterprise Value/Ebitda-2.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Exicure Business Overview & Revenue Model
Company Description
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neur...
How the Company Makes Money
null...
Exicure Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 500.00K | 0.00 | 28.83M | -483.00K |
| Gross Profit | -460.00K | 500.00K | -1.42M | 26.97M | -483.00K |
| EBITDA | -9.66M | -8.85M | -15.54M | 78.00K | -60.63M |
| Net Income | -4.95M | -9.70M | -16.91M | -2.58M | -64.10M |
Balance Sheet | |||||
| Total Assets | 14.04M | 15.06M | 11.58M | 23.33M | 64.87M |
| Cash, Cash Equivalents and Short-Term Investments | 3.75M | 12.51M | 816.00K | 8.58M | 39.14M |
| Total Debt | 176.00K | 5.93M | 6.67M | 7.31M | 14.74M |
| Total Liabilities | 10.12M | 8.28M | 8.55M | 8.41M | 53.64M |
| Stockholders Equity | 3.93M | 6.77M | 3.03M | 14.92M | 11.23M |
Cash Flow | |||||
| Free Cash Flow | -8.56M | -2.91M | -10.36M | -35.67M | -35.79M |
| Operating Cash Flow | -8.55M | -2.91M | -10.36M | -35.66M | -34.82M |
| Investing Cash Flow | -1.81M | 0.00 | -1.08M | 4.70M | 43.09M |
| Financing Cash Flow | 1.60M | 13.40M | 3.67M | -3.10M | 1.12M |
Exicure Technical Analysis
Negative
5.93
Price Trends
4.23
Negative
4.76
Negative
5.23
Negative
Market Momentum
0.03
Positive
46.56
Neutral
12.04
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XCUR, the sentiment is Negative. The current price of 5.93 is above the 20-day moving average (MA) of 4.35, above the 50-day MA of 4.23, and above the 200-day MA of 5.23, indicating a bearish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 46.56 is Neutral, neither overbought nor oversold. The STOCH value of 12.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XCUR.
Exicure Risk Analysis
Exicure disclosed 22 risk factors in its most recent earnings report. Exicure reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Exicure Peers Comparison
UnderperformOutperform
Sector (51)
XCUR
Exicure
4.19
-8.61
-67.27%
UNCY
Unicycive Therapeutics
6.93
2.32
50.33%
CRBU
Caribou Biosciences
1.94
1.18
155.26%
Exicure Corporate Events
Business Operations and StrategyLegal Proceedings
Exicure Reaches Preliminary Settlement in Derivative Lawsuits
Positive
Apr 2, 2026
On March 19, 2026, the U.S. District Court for the Northern District of Illinois preliminarily approved a settlement of stockholder derivative claims brought on behalf of Exicure, Inc. The settlement is designed to fully and finally resolve deriva...
Executive/Board Changes
Exicure Announces Routine Board and Audit Committee Change
Neutral
Mar 27, 2026
On March 25, 2026, Exicure director Sangjin Yeo submitted his resignation from the company’s Board of Directors and its Audit Committee, effective March 27, 2026. The company stated that Yeo’s departure was not due to any disagreement ...
Business Operations and StrategyExecutive/Board Changes
Exicure Announces New CEO and Interim CFO Appointments
Neutral
Feb 17, 2026
On February 11, 2026, Exicure, Inc. appointed Jung Soo Kim as Chief Executive Officer and President and named Gyuyeob Lee as Interim Chief Financial Officer and Secretary, following the February 9, 2026 resignations of former CEO and President And...
Executive/Board Changes
Exicure Announces Major Leadership and Board Restructuring
Negative
Feb 10, 2026
Exicure announced that on February 6, 2026, board members Andy Yoo, Seung Ik Baik, and Aejin Hwang resigned from the Board of Directors, effective February 9, 2026, with the company stating the departures were not due to disagreements over operati...
Business Operations and StrategyProduct-Related Announcements
Exicure Achieves Milestone in Burixafor Phase 2 Program
Positive
Jan 22, 2026
On January 16, 2026, Exicure completed the first contractual milestone under its collaboration with GPCR Therapeutics by finishing a Phase 2 clinical trial of its novel stem cell mobilizer, Burixafor (GPC‑100), and submitting the clinical st...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.